Real-world outcomes in metastatic renal cell carcinoma: Insights from a joint community-academic registry

Journal of Oncology Practice

Volumn 10, Issue 2, 2014, Pages

  Harrison, Michael R ^a   Hirsch, Bradford R ^a   George, Daniel J ^a   Walker, Mark S ^a   Chen, Connie ^a   Korytowsky, Beata ^a   Stepanski, Edward ^a   Abernethy, Amy P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; COHORT ANALYSIS; DEATH; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REGISTER; AGED; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SURVIVAL; UNITED STATES;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NORTH CAROLINA; OUTCOME ASSESSMENT (HEALTH CARE); PROTEIN KINASE INHIBITORS; REGISTRIES; SURVIVAL ANALYSIS; TENNESSEE;

EID: 84904514187     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2013.001180     Document Type: Article

References (30)

1. Agency for Healthcare Research and Quality: What is comparative effectiveness research? http://effectivehealthcare.ahrq.gov/index.cfm/what-is- comparative-effectiveness-research1/
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
3. Rouvière O, Bouvier R, Négrier S, et al: Nonmetastatic renal-cell carcinoma: Is it really possible to define rational guidelines for post-treatment follow-up? Nat Clin Pract Oncol 3:200-213, 2006
4. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
5. Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. The Oncologist 16:14-22, 2011 (suppl 2)
6. Mulders P: Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: Differences and synergies of two targeted mechanisms. BJU Int 104:1585-1589, 2009
7. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
8. Escudier B, Bellmunt J, Négrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010
9. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 3556:125-134, 2007 (Pubitemid 46089673)
10. Heng DY, Choueiri TK, Lee J-L, et al: An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. J Clin Oncol 30:286s, 2012 (suppl 5; abstr 4536)
11. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
12. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
13. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
14. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
15. Hudes GR, Carducci MA, Choueiri TK, et al: NCCN Task Force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Cancer Netw 9:S1-S29, 2011 (suppl 1)
16. Sonpavde G, Choueiri TK, Escudier B, et al: Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy? Eur Urol 61:307-316, 2012
17. Hosmer DW, Lemeshow S: Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons, 2008
18. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 10:757-763, 2009
19. Manola J, Royston P, Elson P, et al: Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the International Kidney Cancer Working Group. Clin Breast Cancer 17:5443-5450, 2011
20. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832-841, 2005 (Pubitemid 46224183)
21. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999 (Pubitemid 29368255)
22. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
23. National Comprehensive Cancer Network: Kidney cancer. National Comprehensive Cancer Network and American Cancer Society; 012
24. Busch J, Seidel C, Kempkensteffen C, et al: Sequence therapy in patients with metastatic renal cell carcinoma: Comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 60:1163-1170, 2011
25. Heng DY, Lee J-L, Harshman LC, et al: A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30, 2012 (suppl 5; abstr 387)
26. Hutson TE, Escudier B, Esteban E, et al: Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: Results from the INTORSECT Trial. Presented at the European Society for Medical Oncology Congress, Vienna, Austria, September 28-October 2, 2012
27. Buchler T, Klapka R, Melichar B, et al: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol 23:395-401, 2011
28. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
29. Escudier BJ, Belldegrun AS, Melichar B, et al: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:239s, 2009 (abstr 5020)
30. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27:289s, 2009 (abstr 5019)